Cargando…
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
BACKGROUND: CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. METHOD...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083309/ https://www.ncbi.nlm.nih.gov/pubmed/32196516 http://dx.doi.org/10.1371/journal.pone.0230306 |
_version_ | 1783508504964759552 |
---|---|
author | DeLeon, Thomas T. Almquist, Daniel R. Kipp, Benjamin R. Langlais, Blake T. Mangold, Aaron Winters, Jennifer L. Kosiorek, Heidi E. Joseph, Richard W. Dronca, Roxana S. Block, Matthew S. McWilliams, Robert R. Kottschade, Lisa A. Rumilla, Kandelaria M. Voss, Jesse S. Seetharam, Mahesh Sekulic, Aleksandar Markovic, Svetomir N. Bryce, Alan H. |
author_facet | DeLeon, Thomas T. Almquist, Daniel R. Kipp, Benjamin R. Langlais, Blake T. Mangold, Aaron Winters, Jennifer L. Kosiorek, Heidi E. Joseph, Richard W. Dronca, Roxana S. Block, Matthew S. McWilliams, Robert R. Kottschade, Lisa A. Rumilla, Kandelaria M. Voss, Jesse S. Seetharam, Mahesh Sekulic, Aleksandar Markovic, Svetomir N. Bryce, Alan H. |
author_sort | DeLeon, Thomas T. |
collection | PubMed |
description | BACKGROUND: CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. METHODS: All patients with cutaneous melanoma or melanoma of unknown primary who received checkpoint inhibitor therapy and underwent genomic profiling with the 50-gene Mayo Clinic solid tumor targeted cancer gene panel were included. Patients were stratified according to the presence or absence of mutations in BRAF, NRAS, CDKN2A, and TP53. Patients without mutations in any of these genes were termed quadruple wild type (Quad(WT)). Clinical outcomes including median time to progression (TTP), median overall survival (OS), 6-month and 12-month OS, 6-month and 12-month without progression, ORR and disease control rate (DCR) were analyzed according to the mutational status of CDKN2A, TP53 and Quad(WT). RESULTS: A total of 102 patients were included in this study of which 14 had mutations of CDKN2A (CDKN2A(mut)), 21 had TP53 mutations (TP53(mut)), and 12 were Quad(WT). TP53(mut), CDKN2A(mut) and Quad(WT) mutational status did not impact clinical outcomes including median TTP, median OS, 6-month and 12-month OS, 6-month and 12-month without progression, ORR and DCR. There was a trend towards improved median TTP and DCR in CDKN2A(mut) cohort and a trend towards worsened median TTP in the Quad(WT) cohort. CONCLUSION: Cell cycle regulators such as TP53 and CDKN2A do not appear to significantly alter clinical outcomes when immune checkpoint inhibitors are used. |
format | Online Article Text |
id | pubmed-7083309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-70833092020-03-24 Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations DeLeon, Thomas T. Almquist, Daniel R. Kipp, Benjamin R. Langlais, Blake T. Mangold, Aaron Winters, Jennifer L. Kosiorek, Heidi E. Joseph, Richard W. Dronca, Roxana S. Block, Matthew S. McWilliams, Robert R. Kottschade, Lisa A. Rumilla, Kandelaria M. Voss, Jesse S. Seetharam, Mahesh Sekulic, Aleksandar Markovic, Svetomir N. Bryce, Alan H. PLoS One Research Article BACKGROUND: CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. METHODS: All patients with cutaneous melanoma or melanoma of unknown primary who received checkpoint inhibitor therapy and underwent genomic profiling with the 50-gene Mayo Clinic solid tumor targeted cancer gene panel were included. Patients were stratified according to the presence or absence of mutations in BRAF, NRAS, CDKN2A, and TP53. Patients without mutations in any of these genes were termed quadruple wild type (Quad(WT)). Clinical outcomes including median time to progression (TTP), median overall survival (OS), 6-month and 12-month OS, 6-month and 12-month without progression, ORR and disease control rate (DCR) were analyzed according to the mutational status of CDKN2A, TP53 and Quad(WT). RESULTS: A total of 102 patients were included in this study of which 14 had mutations of CDKN2A (CDKN2A(mut)), 21 had TP53 mutations (TP53(mut)), and 12 were Quad(WT). TP53(mut), CDKN2A(mut) and Quad(WT) mutational status did not impact clinical outcomes including median TTP, median OS, 6-month and 12-month OS, 6-month and 12-month without progression, ORR and DCR. There was a trend towards improved median TTP and DCR in CDKN2A(mut) cohort and a trend towards worsened median TTP in the Quad(WT) cohort. CONCLUSION: Cell cycle regulators such as TP53 and CDKN2A do not appear to significantly alter clinical outcomes when immune checkpoint inhibitors are used. Public Library of Science 2020-03-20 /pmc/articles/PMC7083309/ /pubmed/32196516 http://dx.doi.org/10.1371/journal.pone.0230306 Text en © 2020 DeLeon et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article DeLeon, Thomas T. Almquist, Daniel R. Kipp, Benjamin R. Langlais, Blake T. Mangold, Aaron Winters, Jennifer L. Kosiorek, Heidi E. Joseph, Richard W. Dronca, Roxana S. Block, Matthew S. McWilliams, Robert R. Kottschade, Lisa A. Rumilla, Kandelaria M. Voss, Jesse S. Seetharam, Mahesh Sekulic, Aleksandar Markovic, Svetomir N. Bryce, Alan H. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations |
title | Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations |
title_full | Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations |
title_fullStr | Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations |
title_full_unstemmed | Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations |
title_short | Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations |
title_sort | assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with cdkn2a and tp53 pathogenic mutations |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083309/ https://www.ncbi.nlm.nih.gov/pubmed/32196516 http://dx.doi.org/10.1371/journal.pone.0230306 |
work_keys_str_mv | AT deleonthomast assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT almquistdanielr assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT kippbenjaminr assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT langlaisblaket assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT mangoldaaron assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT wintersjenniferl assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT kosiorekheidie assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT josephrichardw assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT droncaroxanas assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT blockmatthews assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT mcwilliamsrobertr assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT kottschadelisaa assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT rumillakandelariam assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT vossjesses assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT seetharammahesh assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT sekulicaleksandar assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT markovicsvetomirn assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations AT brycealanh assessmentofclinicaloutcomeswithimmunecheckpointinhibitortherapyinmelanomapatientswithcdkn2aandtp53pathogenicmutations |